FTC Targets Supplement Firm In Administrative Proceeding After Contempt Complaint Fails
Federal Judge Says Settlement Stipulation Against ‘Treats Disease’ Claims Is Ambiguous
Executive Summary
A ruling in Maine federal court questions whether FTC could show firms made claims a product labeled as a supplement “cures, mitigates, or treats any disease." But agency's administrative complaint includes the same phrase as a stipulation among the penalties it would order.
You may also be interested in...
Supplement Firms Agree To Leave Market After Being Released From FTC Contempt Complaint
FTC announces Health Research Laboratories, Whole Body Supplements and their owner, Kramer Duhon, agree to settlement in administrative proceeding opened in November 2020 after federal judge dismissed contempt complaint from 2018 settlement.
Arizona Cannabinoid Supplement Firm Agrees To Stop After Acknowledging 34 False Claims
Arizona CBD marketer Kushly Industries is ordered to no longer make disease claims for products without competent and reliable scientific evidence. Settlement lists 16 examples of claims but order in US district court identifies 32 claims the firm acknowledged it used in advertising.
Supplement Firms Launch New Brands, But Charged With Same Violations By FTC
Firms allegedly made false claims for four products labeled as supplements they launched since 2018 settlement. “Brazenly ignoring the Court’s order barring them from making unsubstantiated claims,” firms “have continued promoting their products with outrageous claims,” FTC contends.